[Russian experience in using a combination of fixed doses of donepezil and memantine in the treatment of Alzheimer's disease as an observational non-interventional multicenter program].

Objective: To evaluate the efficacy, safety, and compliance to therapy with Mioreol, first used as part of routine clinical practice in patients with moderate-to-severe dementia due to AD.

Material And Methods: The study was conducted as a non-interventional observational program. The work was performed on a group of 48 patients with moderate-to-severe AD aged from 60 to 90 years (median age 74 [69; 77]).

[Cerebrolysin Treatment Reduces the Risk of Mild Cognitive Decline to Dementia in 1st-Degree Relatives of Alzheimer's Patients: A Prospective Comparative Study].

Objective: To evaluate the long-term effects of annual course therapy with Cerebrolysin on cognitive functioning and the risk of transition to dementia in relatives of patients with Alzheimer's disease (AD) with amnestic-type mild cognitive decline syndrome (aMCI) in comparison with the same group untreated relatives.

Material And Methods: The cohort included 88 first-degree relatives of BA patients with aMCI syndrome aged 50 to 82 years (mean age 65.0±9.

[The impact of BMI on the course of the acute SARS-COV-2 infection and the risks that emerge during the first year after the hospital discharge. Subanalysis evidence of the AKTIV and AKTIV 2 registries].

Background: There is enough evidence of the negative impact of excess weight on the formation and progression of res piratory pathology. Given the continuing SARS-CoV-2 pandemic, it is relevant to determine the relationship between body mass index (BMI) and the clinical features of the novel coronavirus infection (NCI).

Aim: To study the effect of BMI on the course of the acute SARS-COV-2 infection and the post-covid period.

[ACTIV SARS-CoV-2 registry (Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients). Assessment of impact of combined original comorbid diseases in patients with COVID-19 on the prognosis].

Aim: Study the impact of various combinations of comorbid original diseases in patients infected with COVID-19 later on the disease progression and outcomes of the new coronavirus infection.

Materials And Methods: The ACTIV registry was created on the Eurasian Association of Therapists initiative. 5,808 patients have been included in the registry: men and women with COVID-19 treated at hospital or at home.

Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma.

The authors describe the developmental process of intravenous anti-COVID-19 hyperimmune immunoglobulin from anti-SARS-CoV-2 neutralizing antibody-containing plasma. Furthermore, the authors investigated its safety and protective activity in animal models. The manufacturing process included standard ethanol fractionation, chromatographic purification steps and virus removal or inactivation.

[Citicoline in the treatment of cognitive impairment in first-degree relatives of AD patients: the influence of the ApoE genotype].

Objective: To study the effects of a three-month course of therapy with citicoline, aimed at preventing the progression of cognitive deficit in 1st-degree relatives of patients with Alzheimer's disease (AD), depending on the carriage of the (+) genotype.

Material And Methods: Study participants: 82 blood relatives of AD patients, 66 of them with signs of minimal cognitive dysfunction (group 1) objectively confirmed by clinical neuropsychological examination and 16 people with mild cognitive decline syndrome (group 2). Open comparative multidisciplinary study of the dynamics of cognitive status in relatives of AD patients who received a three-month course of citicoline therapy.

Analysis of influence of background therapy for comorbidities in the period before infection on the risk of the lethal COVID outcome. Data from the international ACTIV SARS-CoV-2 registry («Analysis of chronic non-infectious diseases dynamics after COVID-19 infection in adult patients SARS-CoV-2»).

Aim      To study the effect of regular drug therapy for cardiovascular and other diseases preceding the COVID-19 infection on severity and outcome of COVID-19 based on data of the ACTIVE (Analysis of dynamics of Comorbidities in paTIents who surVived SARS-CoV-2 infEction) registry.Material and methods  The ACTIVE registry was created at the initiative of the Eurasian Association of Therapists. The registry includes 5 808 male and female patients diagnosed with COVID-19 treated in a hospital or at home with a due protection of patients' privacy (data of nasal and throat smears; antibody titer; typical CT imaging features).

[Left ventricular global function index as a predictor of adverse cardiovascular events in patients with acute coronary syndrome].

Aim      To evaluate the prognostic significance of the left ventricular global function index (LV GFI) in patients with acute coronary syndrome (ACS) using echocardiography (EchoCG).Material and methods             The LV GFI is an index that integrates LV cavity volumes, stroke volume, and myocardial volume. This study included 2169 patients with ACS (1340 (61.

Magnetic and magneto-thermal properties of ferrimagnetic alloys (ErY)(CoFe)and their dependence on the orientations of resultant and sublattice magnetizations.

In this paper structure, magnetic and magneto-thermal properties: magnetic entropy change (Δ) and refrigeration capacity () of ErY(CoFe)alloys (= 0, 0.2, 0.4, 0.

[Distracter inhibition in mild cognitive impairment].

Objective: To study the effectiveness of interfering visual stimuli inhibition using the flanker task in a group of healthy young and healthy old participants, and in a group of participants with mild cognitive impairment (MCI).

Material And Methods: Reaction times and accuracy, as well as the diffusion model of reaction times with parameters reflecting perceptual and motor processes, stimulus processing speed, and conservativeness of response selection were analyzed.

Results: We found reduced speed and accuracy in older age, especially in MCI patients.

[Features of the conflict adaptation effect in mild cognitive decline.].

Conflict adaptation effect in interference control tasks (like Stroop task or flanker task) consists in better interference suppression in incongruent trials following an incongruent trial. In a flanker task is shown that in normal cognitive aging there is a null conflict adaptation effect and that in mild cognitive impairment there is a reversed (negative) conflict adaptation effect. Using the drift diffusion model of reaction time, it is shown that the change in conflict adaptation effect in mild cognitive impairment is associated with the absence of adaptive increase in processing speed in the presence of distractors.

[Delayed effects of cerebrolysin in the prevention of cognitive impairment progression in the first degree relatives of patients with Alzheimer's disease: the role of the ApoE genotype].

Objective: To assess the delayed effect of course therapy with cerebrolysin on the cognitive functioning of the first degree relatives of patients with Alzheimer's disease (AD), including, depending on the ApoE4 genotype.

Material And Methods: A cohort of 72 blood relatives of patients with AD, including 46 with objectively confirmed clinical and neuropsychological examination signs of mild cognitive dysfunction (group 1) and 26 (group 2) with cognitive impairment that meets the diagnostic criteria of mild cognitive impairment (ICD-10 F06.7), was studied.

Increased local switch costs in mild cognitive impairment.

Task switching performance was assessed in a group of healthy young, healthy old, and MCI-diagnosed participants. Highly significant RT-related local switch costs were found in the MCI group. This contrasts the typical finding that in normal aging local switch costs show no age-related deficit.

[Prevention of progression of cognitive decline in the first-degree relatives of patients with Alzheimer's disease].

Aim: To evaluate the efficacy of course neurotrophic therapy with cerebrolysin in a group of first-degree relatives of Alzheimer's disease (AD) patients who had minimal cognitive dysfunction.

Material And Methods: Sixty-seven relatives (mean age 57.6±14.

[Clinical efficacy and safety of choline alfoscerate in the treatment of late-onset cognitive impairment].

Aim: To study the efficacy and safety of cereton (choline alfoscerate) in the treatment of elderly patients with amnestic type of mild cognitive impairment (aMCI), which often represents a pre-dementia (symptomatic) stage of Alzheimer's disease (AD).

Material And Methods: Fifty patients (40 women and 10 men; mean age 68,8 years) received three-month therapy with cereton in a dose of 1200 mg/day in 3 divided doses. Fifteen patients received the same treatment again within 1 year.

[Anti-inflammatory effects of neurotrophic therapy (a pilot study)].

Aim: To study clinical effects of cerebrolysin and its impact on systemic inflammation markers and immunity in mild cognitive impairment (MCI).

Material And Methods: Twenty patients with MCI were treated with cerebrolysin administered intravenously during 4 weeks. Serum levels of immunoglobulins, inflammatory markers, neurotrophic factors were measured in dynamics in patients and controls using ELISA.

[Therapeutic monitoring and prediction of the efficacy of neurotrophic treatment in patients with amnestic type of mild cognitive impairment].

Aim: To perform therapeutic monitoring and prediction of the neurotrophic therapy efficacy in patients with amnestic type of mild cognitive impairment (aMCI) in a model of course cerebrolysin therapy.

Material And Methods: The study involved a group of 19 elderly patients who met the diagnostic criteria of aMCI. All patients received a course of neurotrophic therapy consisting of 20 intravenous infusions of cerebrolysin (30 ml of cerebrolysin in 100 ml of isotonic sodium chloride solution).

[Detection of effective treatment of amnestic mild cognitive impairement with cereton by testing of lipids markers].

Aim: Determination of effectivity and safety of Cereton (Choline alfoscerate, production by Sotex) 1200 mg/day in the treatment of cognitive functioning disorders in patients with amnestic mild cognitive impairment (aMCI) and determining its influence in the process (after a 3 month course of taking the drug) and 3 months after the end of treatment of aMCI on the change in the content of phosphatidylcholine, sphingomyelin, ceramide-metabolite sphingolipids and the activity of genes controlling the synthesis of enzymes, which control ithe metabolism of sphingomyelin and ceramide (sphingomyelinase and ceramidase).

Material And Methods: The study involved a group of elderly patients (20 people), consisting of 14 women and 6 men, aged 51 to 82 years (mean age 70.3±9.

Suppression and inducement of the charge-density-wave state in Cr x TiSe2.

The x-ray diffraction, electrical resistivity and thermal expansion measurements have been employed to study how the intercalation of Cr atoms into TiSe2 matrix affects the crystal structure, formation of the charge density wave (CDW) and electrical properties. The intercalation of a small amount of Cr atoms (up to x ~ 0.03) is observed to suppress the CDW formation.

[Levels of proinflammatory cytokines and vascular endothelial growth factor in patients with Alzheimer's disease and mild cognitive impairment].

Objective: to evaluate the levels of cytokines (IFNα, IFNγ, IL-2, Il-4, IL-6, IL-8, IL-10, IL-12, IL-15), IL-1β receptor antagonist (IL-1RA), vascular endothelial growth factor (VEGF) and its antagonist, the soluble form of receptor 1 (sVEGFR1) in the blood serum of patients with Alzheimer's disease, with early onset (ADEO) and late onset (ADLO), and in patients with mild cognitive impairment (MCI).

Material And Methods: Levels of interleukins, IL-1RA, VEGF and sVEGFR1 were measured in 20 patients with AD and 11 patients with MCI using ELISA. These parameters were compared to the severity of cognitive impairment assessed by the performance on neurocognitive tests.

[Clinical experience of the use of memantal in patients with moderate and severe Alzheimer's disease].

Objective: To assess the efficacy and safety of memantal, a generic formulation of memantine, in patients with moderate and severe dementia due to Alzheimer's disease (AD).

Material And Methods: Thirty patients with moderate and severe AD, aged from 55 to 84 years, were examined. Memantal was used in the dose of 20 mg per day after the titration period.

Layer-preferential substitutions and magnetic properties of pyrrhotite-type Fe7-yMyX8 chalcogenides (X = S, Se; M = Ti, Co).

A comparative study of four series of pyrrhotite-type chalcogenide compounds Fe(7-y)M(y)X(8) (X = S, Se) with substitution of Ti or Co for iron has been performed by means of x-ray and neutron powder diffraction, and by magnetization measurements. In Fe(7-y)M(y)X(8) compounds having a ferrimagnetic order at y = 0, the substitution of either Ti or Co for iron is observed to result in a monotonous decrease of the magnetic ordering temperature, while the resultant magnetization shows a non-monotonous behavior with a minimum around y = 1.0-1.

[The reduced level of antibodies to acetylcholine receptor alpha 7 fragment in the blood serum of patients with Alzheimer's disease].

Objective: Determination of antibodies to neuronal membrane proteins in the blood serum of patients is of interest for diagnosis and optimization of treatment of Alzheimer's disease (AD). Authors studied the level of antibodies to acetylcholine receptor alpha 7 protein fragment (AChR), prion protein (РrР) and glycation end-products (RAGE) as well as to intracellular proteins nucleophosmin (Nuc) and survivin (Sur) in the serum of AD patients.

Material And Methods: Serum samples of 26 patients with probable AD and 13 healthy people were studied.

[Clinical experience with agomelatine for the treatment of depression in elderly patients in outpatient practice].

Unlabelled: Objective. To determine the therapeutic efficacy and safety of agomelatine (valdoxan) in elderly patients with mild and moderate depression during outpatient treatment. Material and methods.

Study of Alzheimer family case reveals hemochromotosis-associated HFE mutation.

We report a family case of type II early-onset Alzheimer's disease (AD) inherited over three generations. None of the patients in the family had mutations in the genes believed to be the major risk factors for AD, such as APP, presenilin 1 or 2. Targeted exome sequencing of 249 genes that were previously reported to be associated with AD revealed a rare mutation in hemochromatosis (HFE) gene known to be associated with hemochromotosis.